KRAS and cancer: In the Stand Up To Cancer (SU2C) cohort of 174 patients treated with nivolumab, patients treated with nivolumab with STK11/LKB1 comutation had significantly lower objective response rates (7.4% vs. 28.6%), median PFS (1.8 vs. 2.7 months), and median OS (6.4 vs. 16.1 months) compared with the KRAS-mutated, LKB1 wild-type patients.